BXCL501: Clinical Trials

3 trials of BXCL501, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Terminated 1

Follow BXCL501: new trials by email Literature Review of BXCL501 trials Research Report on BXCL501

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
BXCL501, Matching Placebo - Agitation, Dementia
Phase 3TerminatedBioXcel Therapeutics Inc132022-12-052026-10-01
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
BXCL501, Matching Placebo - Agitation,Psychomotor, Bipolar I Disorder
Phase 3CompletedBioXcel Therapeutics Inc4522022-11-212026-08-07
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
BXCL501, Matching Placebo - Agitation, Dementia
Phase 3CompletedBioXcel Therapeutics Inc1512022-04-272026-08-11

Conditions studied

Psychomotor Agitation (3)  ·  Dementia (2)  ·  Bipolar Disorder (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia (1)

Sponsors

BioXcel Therapeutics Inc (3)

Countries

United States (3)

Top investigators

BioXcel MM (1)  ·  BioXcel MM, MD (1)  ·  Robert Risinger, MD (1)